Charisse Symmonds, DO
Internal Medicine · Emporia, KSNPI 1366675910
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,343 of the $14,187 with a category attached, or 72.9%. Dexcom, Inc. accounts for 76.3% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $7,065, more than ten times the $644 reported in 2019. Among internal medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $50.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$11K
- Novo Nordisk$857
- Corcept Therapeutics$544
- Lilly USA, LLC$352
- AbbVie$302
- Novartis$217
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$10,34373%
- Travel & lodging$2732%
- Food & beverage$3,46524%
- Education$1071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 24 | $10,820 |
| Novo Nordisk | 82 | $857 |
| Corcept Therapeutics | 29 | $544 |
| Lilly USA, LLC | 39 | $352 |
| AbbVie | 29 | $302 |
| Novartis | 14 | $217 |
| Insulet Corporation | 8 | $149 |
| Bayer | 6 | $107 |
| Johnson & Johnson | 4 | $92 |
| Boehringer Ingelheim | 5 | $82 |
| Pfizer | 5 | $78 |
| AstraZeneca | 5 | $76 |
| Cequr Corporation | 1 | $58 |
| Averitas Pharma Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Amgen | 3 | $45 |
| Merck | 2 | $45 |
| Viatris Specialty LLC | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Medtronic | 2 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$9,077
- DEXCOM STELO GLUCOSE BIOSENSOR$5,962
- DEXCOM G6 CGM SYSTEM$1,400
How this compares
$14,187 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 48 | $1,219,972 |
| OzempicSemaglutide | 101 | $110,979 |
| MounjaroTirzepatide | 84 | $98,347 |
| JardianceEmpagliflozin | 78 | $74,004 |
| EliquisApixaban | 49 | $34,513 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $22,586 |
| TrulicityDulaglutide | 14 | $19,545 |
| FarxigaDapagliflozin Propanediol | 22 | $15,203 |
| MyrbetriqMirabegron | 14 | $8,925 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $8,629 |
| TrintellixVortioxetine Hydrobromide | 20 | $5,052 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,789 |
| Novolog FlexpenInsulin Aspart | 21 | $3,725 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $3,241 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $544 | $1,219,97248 claims |
| Lilly USA, LLCMounjaro, Trulicity | $352 | $117,89298 claims |
| Novo NordiskOzempic | $857 | $110,979101 claims |
| Boehringer IngelheimJardiance | $82 | $74,00478 claims |
| PfizerEliquis | $78 | $34,51349 claims |
| AstraZenecaFarxiga | $76 | $15,20322 claims |
| Sanofi-aventis U.S. LLCLantus | $21 | $3,24117 claims |
| AbbVieSynthroid | $302 | $1,57542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.
Other internal medicine in Emporia
- Shadi HamdehKansas City$959K
- Donna GriebelLawrence$781K
- Lucas PittsKansas City$235K
- Donna SweetWichita$185K
- Wissam SalibaWichita$155K
- Mark HamblinKansas City$147K
- Atieh JibbeWichita$121K
- Herbert WaxmanOverland Park$82K
- Aaron RohrKansas City$54K
- Raed Al RajabiWestwood$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.